EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Treatment of Intermediate‐Risk Hepatoblastoma Using a Combined Cisplatin and Doxorubicin (PLADO) Regimen and Optimized Surgical Resection

Tomoro Hishiki iD, Kohmei Ida, Kenichiro Watanabe iD, Makiko Mori, Junya Fujimura, Yuki Nogami, Tomoko Iehara iD, Ken Hoshino, Akiko Yokoi, Shohei Honda, Takuro Kazama, Masahiro Sekiguchi und 14 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31770 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Tomoro Hishiki und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Chiba University Graduate School of Medicine, Chiba, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hepatectomy, Hepatoblastoma, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Complete resection of the primary tumor is critical for the survival of children with hepatoblastomas (HBs). This prospective clinical study aimed to clarify the outcome of a chemotherapy regimen comprising cisplatin and doxorubicin (PLADO) followed by definitive surgery conducted at the appropriate time in patients with intermediate‐risk HB.

Methods

Intermediate‐risk HB was defined as patients without evidence of metastatic disease who met any of the following criteria: age ≥3 years; PRETEXT IV disease; presence of more than one PRETEXT annotation factor. The study protocol consisted of four preoperative and two postoperative courses of PLADO. The appropriate surgeries were conducted at optimized timings via real‐time central surgical reviews.

Results

The 3‐year progression‐free and overall survivals of the 33 intermediate‐risk patients included were 78.7% and 87.9%, respectively. Preoperative PLADO resulted in a partial response in 83.9% of the patients. Microscopic complete resection was ultimately obtained in 31 (94%) patients. No patient required more than six preoperative courses before surgery or liver transplantation (LTx). Two patients never had surgery due to tumor progression.

Conclusions

The outcome for patients with intermediate‐risk HB was satisfactory. PLADO, combined with surgery (including LTx) conducted at the optimal time, appeared to cure most patients in this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsHepatectomyHepatoblastomaLiver NeoplasmsAdolescentChildChild, PreschoolFemaleHumansInfantMaleCisplatinCombined Modality TherapyDoxorubicinFollow-Up StudiesPrognosisProspective StudiesSurvival Rate

Stichwörter der Autor:innen

cisplatindoxorubicinhepatoblastomapediatric liver tumor

Substanzen

CisplatinDoxorubicin

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Department of Pediatrics, Teikyo University Mizonokuchi Hospital, Kawanagawa, Japan.
  • Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.
  • Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Department of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan.
  • Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Tomoro Hishiki, Kenichiro Watanabe, Tomoko Iehara, Risa Matsumura, Eiso Hiyama

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Hishiki, T., Ida, K., Watanabe, K., Mori, M., Fujimura, J., Nogami, Y., Iehara, T., Hoshino, K., Yokoi, A., Honda, S., Kazama, T., Sekiguchi, M., Kitagawa, N., Matsumura, R., Nomura, M., Yamada, Y., Hanaki, R., Kaneda, H., Takama, Y., …, & Hiyama, E. (2025). Treatment of Intermediate‐Risk Hepatoblastoma Using a Combined Cisplatin and Doxorubicin (PLADO) Regimen and Optimized Surgical Resection. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31770

Vancouver

Hishiki T, Ida K, Watanabe K, Mori M, Fujimura J, Nogami Y, et al. Treatment of Intermediate‐Risk Hepatoblastoma Using a Combined Cisplatin and Doxorubicin (PLADO) Regimen and Optimized Surgical Resection. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31770

BibTeX
@article{Hishiki2025,
  author = {Hishiki, Tomoro and Ida, Kohmei and Watanabe, Kenichiro and Mori, Makiko and Fujimura, Junya and Nogami, Yuki and Iehara, Tomoko and Hoshino, Ken and Yokoi, Akiko and Honda, Shohei and Kazama, Takuro and Sekiguchi, Masahiro and Kitagawa, Norihiko and Matsumura, Risa and Nomura, Motonari and Yamada, Yohei and Hanaki, Ryo and Kaneda, Hide and Takama, Yuichi and Inoue, Takeshi and Tanaka, Yukichi and Miyazaki, Osamu and Nagase, Hiroki and Takimoto, Tetsuya and Yoshimura, Kenichi and Hiyama, Eiso},
  title = {Treatment of Intermediate‐Risk Hepatoblastoma Using a Combined Cisplatin and Doxorubicin (PLADO) Regimen and Optimized Surgical Resection},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31770}
}
Kostenlos starten →